The acquisition of a multidrug refractory state is a major cause of mortality in myeloma. Myeloma drugs that target the cereblon (CRBN) protein include widely used immunomodulatory drugs (IMiDs), and newer CRBN E3 ligase modulator drugs (CELMoDs), in clinical trials. CRBN genetic disruption causes resistance and poor outcomes with IMiDs. Here, we investigate alternative genomic associations of IMiD resistance, using large whole-genome sequencing patient datasets (n = 522 cases) at newly diagnosed, lenalidomide (LEN)-refractory and lenalidomide-then-pomalidomide (LEN-then-POM)-refractory timepoints. Selecting gene targets reproducibly identified by published CRISPR/shRNA IMiD resistance screens, we found little evidence of genetic disruption by mutation associated with IMiD resistance. However, we identified a chromosome region, 2q37, containing COP9 signalosome members COPS7B and COPS8, copy loss of which significantly enriches between newly diagnosed (incidence 5.5%), LEN-refractory (10.0%), and LEN-then-POM-refractory states (16.4%), and may adversely affect outcomes when clonal fraction is high. In a separate dataset (50 patients) with sequential samples taken throughout treatment, we identified acquisition of 2q37 loss in 16% cases with IMiD exposure, but none in cases without IMiD exposure. The COP9 signalosome is essential for maintenance of the CUL4-DDB1-CRBN E3 ubiquitin ligase. This region may represent a novel marker of IMiD resistance with clinical utility.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653034 | PMC |
| http://dx.doi.org/10.1182/blood.2022015909 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunomodulatory agents (IMiDs) are a major class of drugs for treating multiple myeloma (MM); however, acquired resistance to IMiDs remains a significant clinical challenge. While alterations in cereblon (CRBN) and its pathway are known to contribute to IMiD resistance, they account for only 20-30% of cases, and the underlying mechanisms in the majority of the resistance cases remain unclear. Here, we identified ADAR1 as a novel driver of lenalidomide resistance in MM.
View Article and Find Full Text PDFResistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.
Haematologica
November 2024
Cancer Science Institute of Singapore, National University of Singapore, 117599, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, 119228.
Acquired resistance to immunomodulatory drugs (IMiDs) remains a significant unmet need in the treatment landscape of multiple myeloma (MM). CRBN pathway-dependent mechanisms are known to be vital contributors to IMiD resistance; however, they may account for only a small proportion. Recent research has unveiled additional mechanisms of acquired IMiD resistance that are independent of the CRBN pathway.
View Article and Find Full Text PDFDeep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells.
Sci Rep
October 2024
Department of Hematology and Transplantology, Pomeranian Medical University, 71-252, Szczecin, Poland.
Article Synopsis
- Lenalidomide (LEN) is an effective immunomodulatory drug for multiple myeloma (MM), but patients often develop resistance and relapse over time.
- This study aimed to identify molecular pathways linked to a strong and lasting response to LEN treatment in newly diagnosed MM patients who reached very good partial remission after LEN and dexamethasone therapy.
- Key findings included increased gene expression related to epigenetic mechanisms and immune response, particularly the overexpression of the IL-17 receptor, suggesting potential targets for future therapies to improve the effectiveness of LEN-based treatments.
Bispecific antibodies in the treatment of multiple myeloma.
Blood Cancer J
September 2024
Princess Margaret Cancer Centre, Toronto, ON, Canada.
The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal antibodies like daratumumab along with proteasome inhibitors (PI)s, and immune modulators (IMiD)s have significantly improved survival and outcomes, but also cause unique challenges at the time of relapse. Engaging immune T cells for tumour cell kill with chimeric antigenic T-cell (CAR T-cell) therapy and bispecific antibodies have become important therapeutic options in relapsed multiple myeloma.
View Article and Find Full Text PDFPomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.
Clin Lymphoma Myeloma Leuk
December 2024
John Theurer Cancer Center, Hackensack, NJ. Electronic address:
Article Synopsis
- The study focused on patients with relapsed or refractory multiple myeloma (RRMM) who previously received lenalidomide, examining the effectiveness of a treatment combination involving pomalidomide, daratumumab, and dexamethasone (DPd).
- During the trial, a total of 112 patients were treated, with a median overall survival (OS) of 56.7 months after 41.9 months of follow-up, showing promising results.
- The treatment was generally safe, with adverse events leading to discontinuation in a small percentage of patients, suggesting that this combination therapy could be a viable option for RRMM patients needing further treatment post-lenalidomide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!